Table 5.

Overview complications trials

	Prodisc®		Charité®		FlexiCore®
	Index (n = 162), 82 ♂	Control (n = 80), 34 ♂	Index (n = 205), 113 ♂	Control (n = 99), 44 ♂	Index (n = 44)	Control (n = 23)
Approach-related	2 (2.4%)a	2 (2.5%)	16 (9.1%)a	9 (12.8%)a	1 (2.3%)	0
Prosthesis related	5 (3.1%)	0	8 (3.9%)	10 (10.1%)	2 (4.5%)	0
Treatment related	1 (0.6%)	0	17 (8.3%)	23 (23.2%)	5 (11.4%)	8 (34.8%)
General surgical related	2 (1.2%)	3 (3.8%)	16 (7.8%)	4 (4.0%)	2 (4.5%)	2 (8.7%)
Total of complications	10 (7.3%)	5 (6.3%)	57 (29.1%)	46 (50.2%)	10 (22.7%)	10 (43.5%)
Reoperation at index level	6 (3.7%)	4 (5.4%)	11 (5.4%)	9 (9.1%)	5 (11.4%)	6 (26.1%)
			13 (6.3%)	10 (10.1%)

Table based on the published manuscripts, number of compilation in FDA report [56, 58] deviated (see text)

^aRetrograde ejaculation calculated for men only